Frontiers in Virology 2025

1 papers

Top Research Directions

The 5 research directions with Frontiers in Virology 2025 papers, ranked by paper count, next to 2022. Share is the fraction of the edition’s papers in the direction.

#Direction20252022Share 2025Share 20222022 rank
1How Co-Infecting Pathogens Amplify Disease Severity10100.0%0.0%—
2Incomplete Immune Recovery Despite Successful Viral Suppression10100.0%0.0%—
3Socioeconomic Barriers and the Efficacy Effectiveness Gap10100.0%0.0%—
4The Limits of Single Center Clinical Evidence10100.0%0.0%—
5Therapeutic Simplification through Regimen Consolidation10100.0%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Frontiers in Virology 2025 papers: a paper credits every institution named in its affiliations, once. 2 institutions share 1 credited papers.

#InstitutionPapersShare20222022 rank
1Universidad de Alcalá 1100.0%0—
2University of Verona 1100.0%0—

Download all institutions as CSV

About this data

Papers. Frontiers in Virology 2025 lists 1 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2022 use shares, since the edition went from 1 to 1 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 1 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Frontiers in Virology 2025”, https://lacuna.tiptreesystems.com/venue/frontiers-in-virology/2025.

Papers

Title
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for people with ultra-high viral load of HIV-1: a retrospective real-world cohort study